

AMENDMENTS

Please amend the Claims as follows:

Claims 1-68 (Cancelled)

69. (New) An isolated polypeptide consisting of amino acids 1-285 of SEQ ID NO: 243, wherein 0 to 10 amino acids are independently substituted, deleted or added.

70. (New) The isolated polypeptide of claim 69, wherein 5 to 10 amino acids are independently substituted, deleted or added.

71. (New) The isolated polypeptide of claim 69, wherein 1 to 5 amino acids are independently substituted, deleted or added.

72. (New) The isolated polypeptide of claim 69, wherein 1 to 3 amino acids are independently substituted, deleted or added.

73. (New) The isolated polypeptide of claim 69, wherein 1 or 2 amino acids are independently substituted, deleted or added.

74. (New) An isolated polypeptide which consists of amino acids 1-285 of the amino acid sequence of SEQ ID NO: 243 and either a leader or secretory sequence, a sequence employed for purification or a proprotein sequence.

75. (New) An isolated polypeptide which consists of amino acids 1-285 of the amino acid sequence of SEQ ID NO: 243.

76. (New) A pharmaceutical composition comprising:

a) a polypeptide consisting of amino acids 1-285 of the amino acid sequence of SEQ ID NO: 243, wherein 0 to 10 amino acids are independently substituted, deleted or added, wherein said polypeptide is in an amount effective to induce a protective immunological response against *Streptococcus pneumoniae*; and

b) a pharmaceutically acceptable carrier or excipient.

77. (New) The pharmaceutical composition of claim 76, wherein 5 to 10 amino acids are independently substituted, deleted or added.

78. (New) The pharmaceutical composition of claim 76, wherein 1 to 5 amino acids are independently substituted, deleted or added.

79. (New) The pharmaceutical composition of claim 76, wherein 1 to 3 amino acids are independently substituted, deleted or added.

80. (New) The pharmaceutical composition of claim 76, wherein 1 or 2 amino acids are independently substituted, deleted or added.

81. (New) A pharmaceutical composition comprising:

- a) an isolated polypeptide consisting of amino acids 1-285 of the amino acid sequence of SEQ ID NO: 243 and either a leader or secretory sequence, a sequence employed for purification or a proprotein sequence wherein said polypeptide is in an amount effective to induce a protective immunological response against *Streptococcus pneumoniae*; and
- b) a pharmaceutically acceptable carrier or excipient.

82. (New) A pharmaceutical composition comprising:

- a) an isolated polypeptide consisting of amino acids 1-285 of the amino acid sequence of SEQ ID NO: 243, wherein said polypeptide is in an amount effective to induce a protective immunological response against *Streptococcus pneumoniae*; and
- b) a pharmaceutically acceptable carrier or excipient.

83. (New) The pharmaceutical composition of any one of claims 76-82 further comprising an immunostimulatory substance.

84. (New) An isolated polypeptide consisting of amino acids 15-37, 32-57, 101-121, 115-135, 138-158, 152-172, 220-242 or 236-258 of SEQ ID NO. 243, wherein 0 to 10 amino acids are added.

85. (New) The isolated polypeptide of claim 84, wherein 5 to 10 amino acids are added.
86. (New) The isolated polypeptide of claim 84, wherein 1 to 5 amino acids are added.
87. (New) The isolated polypeptide of claim 84, wherein 1 to 3 amino acids are added.
88. (New) The isolated polypeptide of claim 84, wherein 1 or 2 amino acids are added.
89. (New) An isolated polypeptide which consists of amino acids 15-37, 32-57, 101-121, 115-135, 138-158, 152-172, 220-242 or 236-258 of SEQ ID NO. 243 and either a leader or secretory sequence, a sequence employed for purification or a proprotein sequence.
90. (New) An isolated polypeptide which consists of amino acids 15-37, 32-57, 101-121, 115-135, 138-158, 152-172, 220-242 or 236-258 of SEQ ID NO. 243.
91. (New) A pharmaceutical composition comprising:
- a) a polypeptide consisting of amino acids 15-37, 32-57, 101-121, 115-135, 138-158, 152-172, 220-242 or 236-258 of SEQ ID NO. 243, wherein 0 to 10 amino acids are added, wherein said polypeptide is in an amount effective to induce a protective immunological response against *Streptococcus pneumoniae*; and
 - b) a pharmaceutically acceptable carrier or excipient.
92. (New) The pharmaceutical composition of claim 91, wherein 5 to 10 amino acids are added.
93. (New) The pharmaceutical composition of claim 91, wherein 1 to 5 amino acids are added.
94. (New) The pharmaceutical composition of claim 91, wherein 1 to 3 amino acids are added.
95. (New) The pharmaceutical composition of claim 91, wherein 1 or 2 amino acids are added.
96. (New) A pharmaceutical composition comprising:

a) an isolated polypeptide consisting of amino acids 15-37, 32-57, 101-121, 115-135, 138-158, 152-172, 220-242 or 236-258 of SEQ ID NO. 243 and either a leader or secretory sequence, a sequence employed for purification or a proprotein sequence wherein said polypeptide is in an amount effective to induce a protective immunological response against *Streptococcus pneumoniae*; and

b) a pharmaceutically acceptable carrier or excipient.

97. (New) A pharmaceutical composition comprising:

a) a polypeptide consisting of amino acids 15-37, 32-57, 101-121, 115-135, 138-158, 152-172, 220-242 or 236-258 of SEQ ID NO. 243, wherein said polypeptide is in an amount effective to induce a protective immunological response against *Streptococcus pneumoniae*; and

b) a pharmaceutically acceptable carrier or excipient.

98. (New) The pharmaceutical composition of any one of claims 91-97 further comprising an immunostimulatory substance.